# Cytek Biosciences Inc. (CTKB) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Technology. Price $4.70, market value $611 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Cytek Biosciences Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 3.0×**. Each dollar of revenue is priced at 3.0×.
- **Price / book: 1.9×**. The shares trade at 1.9× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -2.0%** (5-yr avg -0.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 53.2%**. Cytek Biosciences Inc. keeps 53.2% of revenue after the direct cost of what it sells.
- **Operating margin: -21.6%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -33.0%**. The company reported a net loss over the last twelve months.
- **Return on equity: -19.5%**. Return on equity is negative because earnings are negative.
- **Return on assets: -17.5%**. Each dollar of assets produces -17.5% of profit.

## Growth
- **Revenue growth (1 yr): 0.5%** (3-yr 7.1%/yr, 5-yr 16.8%/yr). Revenue grew 0.5% over the last year, against 16.8% a year compounded over five years: growth is slowing.

## Financial health
- **Current ratio: 5.04** (quick 5.04). Current assets cover the next year's liabilities 5.04 times.
- **Altman Z-score: 5.06**. A Z-score of 5.06 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Cytek Biosciences Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (4 analysts). 4 analysts cover Cytek Biosciences Inc.; the consensus is buy, with an average price target of $5.56 (+18% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 18.1%** (YTD -6.9%, 3-mo 14.9%). The shares are up 18.1% over twelve months including dividends.
- **From 52-week high: -23.9%** (43.3% above the low). Trading 24% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 54**. An RSI of 54 is neutral.
- **Beta (1 yr): 1.04** (volatility 57%). Beta of 1.04 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CTKB · Page: https://foliofundamentals.com/stocks/ctkb

Not investment advice.